Gene: PRDM16
Official Full Name: PR/SET domain 16provided by HGNC
Gene Summary: The reciprocal translocation t(1;3)(p36;q21) occurs in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This gene is located near the 1p36.3 breakpoint and has been shown to be specifically expressed in the t(1:3)(p36,q21)-positive MDS/AML. The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal PR domain. The translocation results in the overexpression of a truncated version of this protein that lacks the PR domain, which may play an important role in the pathogenesis of MDS and AML. Alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO03190 | PRDM16 Knockout cell line (HCT 116) | Human | PRDM16 | 1:2~1:4 | Negative | Online Inquiry |
KO03191 | PRDM16 Knockout cell line (HEK293) | Human | PRDM16 | 1:3~1:6 | Negative | Online Inquiry |
PRDM16 Gene Knockout Cell Lines are cutting-edge genetic tools designed to facilitate the exploration of the PRDM16 gene's role in cellular processes. These cell lines have undergone targeted gene disruption through CRISPR-Cas9 technology, resulting in a complete and precise knockout of the PRDM16 gene, which encodes a transcription factor implicated in various biological pathways, including adipogenesis and thermogenesis. By removing PRDM16's functional expression, researchers can observe the resultant phenotypic and molecular changes, enabling a more profound understanding of cellular mechanisms.
The core function of PRDM16 Gene Knockout Cell Lines lies in their ability to model the effects of PRDM16 deficiency in vitro. The mechanisms at play include altered gene expression profiles, resulting in insights into metabolic reprogramming and the differentiation of adipose tissue. These cell lines are invaluable in dissecting the gene's influence on energy homeostasis and potentially identifying therapeutic targets for obesity and metabolic disorders.
In research and clinical settings, the significance of PRDM16 is underscored by its involvement in crucial processes that influence health outcomes, particularly in metabolic diseases. Utilizing these knockout cell lines allows for comprehensive studies that may lead to novel insights into adipose tissue function, as well as their implications in cancer biology and regenerative medicine.
Unlike traditional gene knockout methods that can be slow and imprecise, our PRDM16 Gene Knockout Cell Lines offer rapid results and high specificity, streamlining research processes and ensuring robust data integrity. This product enables researchers and clinicians alike to explore innovative hypotheses while minimizing experimental variability.
For those invested in genetic research and applications in metabolic health, PRDM16 Gene Knockout Cell Lines offer an indispensable resource. Our company, with a commitment to innovation and advancements in biological research tools, ensures that each product is developed under rigorous quality controls, providing exceptional reliability and value in scientific exploration.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.